investorscraft@gmail.com

Intrinsic Value of Adaptimmune Therapeutics plc (ADAP)

Previous Close$0.24
Intrinsic Value
Upside potential
Previous Close
$0.24

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Adaptimmune Therapeutics plc operates in the biotechnology sector, specializing in the development of T-cell therapies for cancer treatment. The company’s core revenue model is driven by strategic collaborations, licensing agreements, and milestone payments from partners, alongside potential future product commercialization. Its lead programs focus on engineered T-cell therapies targeting solid tumors, positioning it in the competitive but high-growth cell therapy market. Adaptimmune differentiates itself through its proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform, which enhances T-cell recognition of cancer cells. The company collaborates with major pharmaceutical firms, leveraging external expertise and funding to advance its pipeline. Despite being pre-revenue from product sales, its partnerships provide critical non-dilutive funding. The cell therapy space is rapidly evolving, with Adaptimmune aiming to carve a niche in solid tumors, an area with significant unmet need and limited effective treatments.

Revenue Profitability And Efficiency

Adaptimmune reported revenue of $178.0 million for FY 2024, primarily from collaboration agreements. The company posted a net loss of $70.8 million, reflecting ongoing R&D investments. Operating cash flow was negative $73.2 million, while capital expenditures were modest at $2.7 million, indicating a focus on conserving liquidity. The diluted EPS of -$0.28 underscores the pre-commercial stage of its pipeline.

Earnings Power And Capital Efficiency

The company’s earnings power remains constrained by high R&D costs, typical of clinical-stage biotech firms. Capital efficiency is supported by collaboration revenue, which offsets some operational expenses. Adaptimmune’s ability to secure partnerships demonstrates confidence in its technology, though profitability hinges on successful clinical outcomes and future commercialization.

Balance Sheet And Financial Health

Adaptimmune holds $91.1 million in cash and equivalents against total debt of $74.2 million, providing a manageable leverage position. The balance sheet reflects a clinical-stage biotech profile, with liquidity focused on funding operations. The absence of dividends aligns with its growth-focused strategy.

Growth Trends And Dividend Policy

Growth is tied to clinical progress and partnership milestones. The company does not pay dividends, reinvesting all cash flows into R&D. Near-term catalysts include data readouts and regulatory advancements for its T-cell therapies, which could drive valuation upside.

Valuation And Market Expectations

The market values Adaptimmune based on its pipeline potential rather than current earnings. Investor sentiment is influenced by clinical trial outcomes and partnership developments. The stock’s performance will likely remain volatile, reflecting binary events in its development cycle.

Strategic Advantages And Outlook

Adaptimmune’s SPEAR T-cell platform and focus on solid tumors provide a differentiated edge. Partnerships with large pharma firms de-risk some R&D costs. The outlook depends on clinical success, with potential for significant upside if its therapies demonstrate efficacy. However, risks include trial failures and competitive pressures in the cell therapy space.

Sources

Company filings, CIK 0001621227

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount